Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer
Status:
Unknown status
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
Pyrotinib is an oral tyrosine kinase inhibitor targeting both EGFR and HER-2 receptors. This
study is designed to evaluate the safety and tolerability of Pyrotinib or Pyrotinib in
combination with Docetaxel in patients with HER2 positive advanced gastric cancer.